𝔖 Bobbio Scriptorium
✦   LIBER   ✦

271 Phase II Study of Thalidomide, interleukin-2 (IL-2), and granulocyte macrophage-colony stimulating factor (GM-CSF) in patients with metastatic renal cell carcinoma (RCC)

✍ Scribed by R. Amato; J. Brown; A. Rawat

Book ID
118621454
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
147 KB
Volume
2
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of subcutaneously adminis
Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
✍ Edward Wos; Thomas Olencki; Laurie Tuason; G. Thomas Budd; David Peereboom; Kate πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 465 KB πŸ‘ 2 views

## BACKGROUND. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that is involved in the differentiation and proliferation of various hematopoietic precursors. It also has been reported to enhance the antitumor activity of various mature effector cells. Previous reports have

Granulocyte-macrophage–colony stimulatin
Granulocyte-macrophage–colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma : Results of two Phase II clinical trials
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Mary C. Dumas; Timothy Kuzel; Walter πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

The aim of this study was to determine the response rates and toxicity of two regimens containing granulocyte-macrophage-colony stimulating factor (GM-CSF) in combination with interleukin-2 (IL-2) in the treatment of patients with metastatic renal cell carcinoma. ## METHODS. Therapy given in the f